Navigation Links
Sinovac Releases Statement on Healive Vaccine Suspension
Date:12/2/2008

BEIJING, Dec. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a leading provider of vaccines in China, announced today that, the Health Services Bureau of Fengtai District in the City of Beijing suspended the use of 83 doses of inactivated hepatitis A vaccine Healive(R), following a report of the death of a minor in the Fengtai District on November 27, 2008, which coincided with the administration of the vaccine two days prior.

The suspended vaccine was part of lot 2008052105 that passed the routine government inspection in July 2008. To date, 19,850 doses vaccines from the lot have been distributed. According to data released by the Center for Adverse Drug Reaction Monitoring of Beijing, there is no other reported adverse reaction to the lot to date. Sinovac has not received, and is not aware of, similar notice of suspension from any other district in Beijing where the lot has been distributed or any other part of China where other lots of the Healive(R) vaccine have been distributed. On November 29, 2008, the Beijing Drug Administration and Drug Administration of Haidian District of City of Beijing conducted a joint administrative investigation that included an inspection of the company's manufacturing site and review of its manufacturing, inspection and sales processes, and concluded in a written report that no abnormality was found.

Sinovac has full confidence in the quality of its products. It will continue to cooperate with government agencies in their investigation of the incident and will provide an update once the investigation is completed.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

    For more information, please contact:

     Helen G. Yang
     Sinovac Biotech Ltd.
     Tel:   +86-10-8289-0088 x871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors/Media:
     Stephanie Carrington / Janine McCargo
     The Ruth Group
     Tel:   +1-646-536-7017/7033
     Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com

'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
2. Sinovac Named to Deloitte Technology Fast 50 China
3. Sinovac to Participate in Two Upcoming Investor Conferences
4. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
5. Sinovac Biotech Holds 2007 Annual General Meeting
6. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
9. Sinovac Adjourns Annual General Meeting
10. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
11. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... effects and diminished effectiveness over time. A recent study published in STEM CELLS ... by stimulating subventricular zone (SVZ) stem cells to produce more neural cells. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, ... Avomeen Analytical Services. Harvill is a distinguished life sciences expert with a proven ... a leader in a wide range of services related to laboratory testing and ...
(Date:3/27/2017)... , March 27, 2017 Infectex Ltd., a Russian portfolio company ... clinical study of SQ109 added to the standard drug therapy regimen in patients with ... at Sequella, Inc. ( USA ) and the US National Institutes of ... ... Maxwell Biotech Venture Fund Logo ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... method to engineer scalable and customizable vascular grafts in JoVE’s Video Journal, the ... lead to new and improved ways of treating coronary artery disease (CAD). Lam ...
Breaking Biology Technology:
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
Breaking Biology News(10 mins):